Ultragenyx
RARE
$44.24
Share price
0.89%
Change (1 day)
4.19%
Change (1 year)
Categories
Ultragenyx (RARE) - Cash on Hand
Cash on Hand as of December 2023 : $0.57 B
According to Ultragenyx's latest financial reports the company has $0.57 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Ultragenyx - Cash on Hand chart (from 2012 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2023-12-31 | $0.57 B | -22.81% |
| 2022-12-31 | $0.74 B | 1.02% |
| 2021-12-31 | $0.74 B | -38.4% |
| 2020-12-31 | $1.20 B | 59.09% |
| 2019-12-31 | $0.75 B | 64.29% |
| 2018-12-31 | $0.45 B | 96.04% |
| 2017-12-31 | $0.23 B | -38.32% |
| 2016-12-31 | $0.38 B | -13.01% |
| 2015-12-31 | $0.43 B | 133.08% |
| 2014-12-31 | $0.18 B | 251.25% |
| 2013-12-31 | $53.37 M | -38.07% |
| 2012-12-31 | $86.19 M | 709.68% |
| 2011-12-31 | $10.64 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Lexicon Pharmaceuticals
LXRX | $0.21 B | -62.16% | 🇺🇸 USA |
 Esperion Therapeutics ESPR | $82.24 M | -85.75% | 🇺🇸 USA |
 Amicus Therapeutics
FOLD | $0.28 B | -50.42% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | $1.07 B | 86.03% | 🇺🇸 USA |